Holen Sie sich die Stockscreener-App
330.44
0.21%
0.6691
Alnylam Pharmaceuticals Inc Aktie (ALNY) Neueste Nachrichten
Alnylam Pharma Appoints New Chief R&D Officer - TipRanks
Alnylam Announces Promotion of Pushkal Garg as Executive Vice President and Chief Research and Development Officer - MarketScreener
Alnylam Promotes Pushkal Garg to Chief Research and Development Officer - citybiz
Alnylam appoints Pushkal Garg as chief research and development officer - Investing.com Australia
Alnylam appoints Pushkal Garg as chief research and development officer By Investing.com - Investing.com Nigeria
Alnylam (ALNY) Names New Chief R&D Officer to Drive Innovation | - GuruFocus
Alnylam Announces Promotion of Pushkal Garg to Chief Research an - GuruFocus
Alnylam Announces Promotion of Pushkal Garg to Chief Research and Development Officer - Business Wire
Alnylam Pharmaceuticals stock hits all-time high at $311.24 By Investing.com - Investing.com Canada
Global RNAi Technology Market: Opportunities in Targeted - openPR.com
Japan’s Isshiki bolsters life sciences practice with senior hire - | Asian Legal Business
Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 20 Years - Benzinga
Antisense Oligonucleotides Market is expected to reach US$ - openPR.com
Exploring High Growth Tech Stocks In The US This June 2025 - simplywall.st
Alnylam Pharmaceuticals’ SWOT analysis: stock poised for growth in expanding ATTR-CM market - Investing.com Canada
Acute Intermittent Porphyria Market Predicted to See Upsurge - openPR.com
From Kentucky farm to founding Biogen: New documentary traces life of Phil Sharp - The Business Journals
Where are the Opportunities in (ALNY) - news.stocktradersdaily.com
Primary Hyperoxaluria Pipeline 2025: FDA Updates, Therapy - openPR.com
Healey boosts life sciences tax incentives as 33 companies plan major expansions - The Business Journals
ALNY Stock: JP Morgan Raises Price Target to $338 | ALNY Stock N - GuruFocus
What 18 Analyst Ratings Have To Say About Alnylam Pharmaceuticals - Benzinga
Homozygous Familial Hypercholesterolemia Market to Reach New - openPR.com
Homozygous Familial Hypercholesterolemia Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Arrowhead Pharma, Novartis, Alnylam Pharma, LIB Therapeutics, Amryt Pharma - The Globe and Mail
JPMorgan Ups Price Target for Alnylam (ALNY) Following Amvuttra Forecast Revision | ALNY Stock News - GuruFocus
Alnylam Wins EC Nod for Label Expansion of Amvuttra for ATTR-CM - MSN
The European Commission Approves Alnylam’s AMVUTTRA - Insider Monkey
John Maraganore joins Axion Bio board to advance cancer therapy By Investing.com - Investing.com Canada
Former Alnylam CEO Who Built $40B Company Backs Instil Bio's Novel Cancer Drug Program - Stock Titan
EC approves Alnylam’s vutrisiran for ATTR-CM treatment - Yahoo Finance
Latest Federal Court Cases: Alnylam Pharmaceuticals, Inc. v. Moderna, Inc. - JD Supra
Dyslipidemia Market to Reach New Heights in Growth by 2034, - openPR.com
Alnylam gets EU approval for Amvuttra in heart disorder treatment - MSN
Alnylam Receives European Commission Approval for AMVUTTRA® (vut - GuruFocus
European Approval Expansion for Alnylam's (ALNY) AMVUTTRA | ALNY Stock News - GuruFocus
Alnylam (ALNY) Secures EU Approval for Amvuttra in Cardiomyopathy - GuruFocus
Transcript : Alnylam Pharmaceuticals, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 09 - MarketScreener
Alnylam Gets EU Approval for RNAi Drug to Treat Transthyretin Amyloidosis With Cardiomyopathy - MarketScreener
EC approves first RNAi therapy for ATTR cardiomyopathy By Investing.com - Investing.com Nigeria
Alnylam Receives European Commission Approval for AMVUTTRA® (vutrisiran) for the Treatment of ATTR Amyloidosis with Cardiomyopathy | ALNY Stock News - GuruFocus
(vutrisiran) for the Treatment of ATTR Amyloidosis with Cardiomyopathy - Business Wire
siRNA on the Precipice as Candidates Reach Beyond the Liver - BioSpace
AMVUTTRA® (vutrisiran) Significantly Reduces Mortality and a Range of Important Cardiovascular Events in Patients with ATTR Amyloidosis with Cardiomyopathy: Additional Data from HELIOS-B - mx.advfn.com
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Alnylam Pharmaceuticals, Inc. (ALNY) - ACCESS Newswire
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Alnylam Pharmaceuticals, Inc. (ALNY) - ACCESS Newswire
Alnylam, Incyte and GSK led biopharma gains amid earnings volatility - BioWorld MedTech
Fed Circ upholds Moderna’s COVID-19 vaccine win against Alnylam - Life Sciences Intellectual Property Review
Moderna Beats Alnylam Appeal In COVID Vaccine Patent Case - Benzinga
Alnylam Fails to Revive Patent Infringement Suit Against Moderna - Bloomberg Law News
Strict Standard for Overriding Patent Lexicography in COVID Vaccine Patent Battle - Patently-O
CAFC Affirms Moderna’s Win, Holding Alnylam Narrowly Defined ‘Branched Alkyl’ - IPWatchdog.com
US appeals court sides with Moderna on COVID patent claims - Reuters
Huntington’s Disease Clinical Trial Pipeline Analysis: 20+ Key Companies Shaping the Future of Dopamine Receptor Antagonists Therapeutics | DelveInsight - GlobeNewswire Inc.
Alnylam Pharmaceuticals (ALNY) Price Target Raised to $500 by H.C. Wainwright - Insider Monkey
(ALNY) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Alnylam stock soars to all-time high of $304.52 By Investing.com - Investing.com South Africa
0.48%
0.40%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):